Drug Class
monoclonal antibody combination
Type
brand
Active Ingredient
tixagevimab and cilgavimab
📋Overview
Evusheld is a combination of two monoclonal antibodies, tixagevimab and cilgavimab, designed to target the spike protein of the SARS-CoV-2 virus. It is associated with the prevention of COVID-19, particularly in individuals who may not mount an adequate immune response to vaccination. Evusheld has been considered for use in populations at higher risk for severe outcomes from COVID-19 infection.
Found an Error?
Help us keep this information accurate. If you notice any incorrect details, please submit a correction request.
Find Discounts for Evusheld
Hospitals.net Disclosure
Hospitals.net is an independent healthcare information platform and does not provide, administer, or guarantee prescription discounts, pricing, coupons, or pharmacy participation. All discount pricing and availability shown above are provided by RxGo and its partners and are subject to change without notice.
Hospitals.net may receive a commission or referral fee if you choose to use this prescription discount service. This does not affect the price you pay at the pharmacy. Hospitals.net is not responsible for pricing accuracy, pharmacy participation, or the fulfillment of any discount offers.
